Immune dysregulation is characteristic of the more severe stages of SARS-CoV-2 infection. Understanding the mechanisms by which the immune system contributes to COVID-19 severity may open new avenues to treatment. Here, we report that elevated IL-13 was associated with the need for mechanical ventilation in 2 independent patient cohorts. In addition, patients who acquired COVID-19 while prescribed Dupilumab, a mAb that blocks IL-13 and IL-4 signaling, had less severe disease. In SARS-CoV-2–infected mice, IL-13 neutralization reduced death and disease severity without affecting viral load, demonstrating an immunopathogenic role for this cytokine. Following anti–IL-13 treatment in infected mice, hyaluronan synthase 1 (Has1) was the most downregulated gene, and accumulation of the hyaluronan (HA) polysaccharide was decreased in the lung. In patients with COVID-19, HA was increased in the lungs and plasma. Blockade of the HA receptor, CD44, reduced mortality in infected mice, supporting the importance of HA as a pathogenic mediator. Finally, HA was directly induced in the lungs of mice by administration of IL-13, indicating a new role for IL-13 in lung disease. Understanding the role of IL-13 and HA has important implications for therapy of COVID-19 and, potentially, other pulmonary diseases. IL-13 levels were elevated in patients with severe COVID-19. In a mouse model of the disease, IL-13 neutralization reduced the disease and decreased lung HA deposition. Administration of IL-13–induced HA in the lung. Blockade of the HA receptor CD44 prevented mortality, highlighting a potentially novel mechanism for IL-13–mediated HA synthesis in pulmonary pathology.
Alexandra N. Donlan, Tara E. Sutherland, Chelsea Marie, Saskia Preissner, Benjamin T. Bradley, Rebecca M. Carpenter, Jeffrey M. Sturek, Jennie Z. Ma, G. Brett Moreau, Jeffrey R. Donowitz, Gregory A. Buck, Myrna G. Serrano, Stacey L. Burgess, Mayuresh M. Abhyankar, Cameron Mura, Philip E. Bourne, Robert Preissner, Mary K. Young, Genevieve R. Lyons, Johanna J. Loomba, Sarah J. Ratcliffe, Melinda D. Poulter, Amy J. Mathers, Anthony J. Day, Barbara J. Mann, Judith E. Allen, William A. Petri Jr.
Title and authors | Publication | Year |
---|---|---|
Chitinase 3-like-1 is a Therapeutic Target That Mediates the Effects of Aging in COVID-19
Suchitra Kamle, Bing Ma, Chuan Hua He, Bedia Akosman, Yang Zhou, Chang-Min Lee, Wafik El-Deiry, Kelsey E. Huntington, Olin D. Liang, Jason Machan, Min-Jong Kang, Hyeon Jun Shin, Emiko Mizoguchi, Chun Geun Lee, Jack A. Elias |
JCI Insight | 2021 |
Pulmonary fibrosis from molecular mechanisms to therapeutic interventions: lessons from post-COVID-19 patients
C Giacomelli, R Piccarducci, L Marchetti, C Romei, C Martini |
Biochemical Pharmacology | 2021 |
Comorbidity-associated glutamine deficiency is a predisposition to severe COVID-19
T Matsuyama, SK Yoshinaga, K Shibue, TW Mak |
Cell Death and Differentiation | 2021 |
Functional Contribution and Targeted Migration of Group-2 Innate Lymphoid Cells in Inflammatory Lung Diseases: Being at the Right Place at the Right Time
S Wirtz, A Schulz-Kuhnt, MF Neurath, I Atreya |
Frontiers in immunology | 2021 |
Cytokine Signature Associated With Disease Severity in COVID-19
J Guo, S Wang, H Xia, D Shi, Y Chen, S Zheng, Y Chen, H Gao, F Guo, Z Ji, C Huang, R Luo, Y Zhang, J Zuo, Y Chen, Y Xu, J Xia, C Zhu, X Xu, Y Qiu, J Sheng, K Xu, L Li |
Frontiers in immunology | 2021 |
Antiviral and Immunomodulatory Effects of Pelargonium sidoides DC. Root Extract EPs® 7630 in SARS-CoV-2-Infected Human Lung Cells
J Papies, J Emanuel, N Heinemann, Ž Kulić, S Schroeder, B Tenner, MD Lehner, G Seifert, MA Müller |
Frontiers in pharmacology | 2021 |
SARS-CoV-2 B.1.1.7 (alpha) and B.1.351 (beta) variants induce pathogenic patterns in K18-hACE2 transgenic mice distinct from early strains
P Radvak, HJ Kwon, M Kosikova, U Ortega-Rodriguez, R Xiang, JN Phue, RF Shen, J Rozzelle, N Kapoor, T Rabara, J Fairman, H Xie |
Nature Communications | 2021 |
COVID-19 in Patients with Atopic Dermatitis Treated with Dupilumab: Three Cases and a Literature Review
J Ceryn, M Niedźwiedź, M Skibińska, M Ciążyńska, A Lesiak, J Narbutt |
Clinical, cosmetic and investigational dermatology | 2021 |
Associations between onychomycosis and COVID-19 clinical outcomes: a retrospective cohort study from a US metropolitan center
U Rakita, T Kaundinya, A Guraya, K Nelson, B Maner, J Manjunath, G Schwartzman, B Lane, JI Silverberg |
Archives of Dermatological Research | 2021 |
Impact of Anti-Type 2 Inflammation Biologic Therapy on COVID-19 Clinical Course and Outcome
D Poddighe, E Kovzel |
Journal of inflammation research | 2021 |
The interplay of fibroblasts, the extracellular matrix, and inflammation in scar formation
Moretti L, Stalfort J, Barker TH, Abebayehu D |
The Journal of biological chemistry | 2021 |